{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T23:27:12Z","timestamp":1648682832623},"reference-count":14,"publisher":"Pharmaceutical Society of Japan","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["YAKUGAKU ZASSHI"],"published-print":{"date-parts":[[2016,6,1]]},"DOI":"10.1248\/yakushi.15-00218","type":"journal-article","created":{"date-parts":[[2016,5,31]],"date-time":"2016-05-31T22:12:48Z","timestamp":1464732768000},"page":"925-929","source":"Crossref","is-referenced-by-count":0,"title":["Pharmaceutical Approach for the Diagnosis and Treatment of Malignant Syndrome: A Case Study"],"prefix":"10.1248","volume":"136","author":[{"given":"Keisuke","family":"Kameda","sequence":"first","affiliation":[{"name":"Depertment of Pharmacy, Matsudo City Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Watarai","sequence":"additional","affiliation":[{"name":"Depertment of Pharmacy, Higashi Matsudo Municipal Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Depertment of Pharmacy, Matsudo City Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohisa","family":"Shoko","sequence":"additional","affiliation":[{"name":"The Shock Trauma and Emergency Medical Center, Matsudo City Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayoshi","family":"Koinuma","sequence":"additional","affiliation":[{"name":"Faculty of Pharmaceutical Science, Teikyo Heisei University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Goro","family":"Ikushima","sequence":"additional","affiliation":[{"name":"Depertment of Pharmacy, Matsudo City Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"163","reference":[{"key":"1","unstructured":"1) Yamawaki S., “Pathogenesis, Diagnosis and Therapy of Neuroleptic Malignant Syndrome,” Shinkoh Igaku Shuppansha Co., Ltd., Tokyo, 1989, pp. 56-65."},{"key":"2","unstructured":"2) UpToDate. Neuroleptic malignant syndrome: 〈http:\/\/www.uptodate.com\/contents\/topic.do?topicKey=NEURO\/4829〉, cited 3 September, 2015."},{"key":"3","unstructured":"3) Ministry of Health, Labour and Welfare, “Manual for handling disorders due to adverse drug reactions, malignant syndrome,” 2008, pp. 1-26."},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Keck P. E. Jr., Pope H. G. Jr., Cohen B. M., McElroy S. L., Nierenberg A. A., Arch. Gen. Psychiatry<\/i>, 46<\/b>, 914-918 (1989).","DOI":"10.1001\/archpsyc.1989.01810100056011"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Britt B. A., Can. Anaesth. Soc. J.<\/i>, 32<\/b>, S40-S41 (1985).","DOI":"10.1007\/BF03009445"},{"key":"6","unstructured":"6) Yamawaki S., “Konnichino Seishinka Chiryoshishin, Akusei Shoukougun,” Seiwa Shoten Co., Ltd., Tokyo, 1997, pp. 184-186."},{"key":"7","unstructured":"7) Astellas Pharma Inc., Dantrolene (Dantrium®<\/sup>) Capsules, Drug Interview Form, July 2015 revised edition."},{"key":"8","unstructured":"8) Astellas Pharma Inc., Dantrolene (Dantrium®<\/sup>) Intravenous Injection, Drug Interview Form, June 2015 revised edition."},{"key":"9","unstructured":"9) Japanese Society of Anesthesiologists, “Guidelines for the Use of Anesthetic Anesthesia Related Drug,” 3rd ed., 4th revision, 2009, pp. 22-24."},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Prakash M. D., Batuk D., Manoj K. S., Mukul R. J., Hitendra S. J., Atul H. B., Chirality<\/i>, 23<\/b>, 955-960 (2011).","DOI":"10.1002\/chir.21022"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Tashiro M., Sakurada Y., Mochizuki H., Iwabuchi K., Aoki M., Sakurai E., Katou M., Itou M., Yanai K., Jpn. J. Clin. Pharmacol. Ther.<\/i>, 34<\/b>, 255S-256S (2003).","DOI":"10.3999\/jscpt.34.2_255S"},{"key":"12","unstructured":"12) Allergic Rhinitis and its Impact on Asthma. “Management of Allergic Rhinitis and Its Impact on Asthma: Pocket Guide.”: 〈http:\/\/www.whiar.org\/docs\/ARIA_PG_08_View_WM.pdf〉, cited 10 June, 2015."},{"key":"13","unstructured":"13) GlaxoSmithKline, SEMPREX-D package insert: 〈http:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=51500008-2034-452c-8e9b-bb112d1b9039〉, DailyMed Web, cited 20 June, 2015."},{"key":"14","unstructured":"14) GlaxoSmithKline, Xyzal Tablets 5 mg, Application for marketing approval: new drug application list of attached documentation. 2.6. Non-clinical written and tabulated summary: 〈http:\/\/www.info.pmda.go.jp\/shinyaku\/P201000063\/34027800_22200AMX00949_H100_1.pdf〉, Pharmaceuticals and Medical Devices Agency Web, cited 15 June, 2015."}],"container-title":["YAKUGAKU ZASSHI"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/yakushi\/136\/6\/136_15-00218\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,9,8]],"date-time":"2018-09-08T11:56:55Z","timestamp":1536407815000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/yakushi\/136\/6\/136_15-00218\/_article\/-char\/ja\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,1]]},"references-count":14,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1248\/yakushi.15-00218","relation":{},"ISSN":["0031-6903","1347-5231"],"issn-type":[{"value":"0031-6903","type":"print"},{"value":"1347-5231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,1]]}}}